The pharmaceutical industry has undergone a fundamental shift from traditional drug discovery methods then characterized by long timelines, high costs, and high failure rates
The pharmaceutical and healthcare industry continues to evolve rapidly, driven by policy changes, strategic investments, scientific breakthroughs, and regulatory developments.
Patients using GLP-1 drugs for obesity and type 2 diabetes may have a slightly higher chance of developing hair loss, according to three new studies.
Drug development fundamentally depends on identifying the right biological target, a target typically a gene, protein, or pathway acts as the intervention point for therapy.
Novartis posted stronger Q2 sales, helped by robust demand for its blockbuster medicines. The Swiss drugmaker also maintained its full-year 2026 outlook.
Intas Pharmaceuticals has achieved a major milestone in India's breast cancer drug market. The company has received CDSCO approval to market its Trastuzumab Emtansine biosimilar in India.
A Rare Brain Disorder linked to Measles is now under the spotlight as a Hyderabad-based institute launches a new Research Study.
Tatva Chintan's Q1 Surprise pushed the company's shares up by 18% on strong first-quarter earnings. Tatva Chintan gained 18.13% to Rs 1,687 after reporting sharp growth in profit and revenue.
People with type 2 diabetes face a higher severe dengue risk, according to a new study. Researchers found the condition can increase the chances of dangerous dengue complications.
Novo Nordisk’s Wegovy gains CDSCO approval for MASH in India, marking a key GLP-1 expansion into liver disease, strengthening its role in metabolic disorder treatment.
.jpg)
, CDSCO.jpg)